Evidence map›Paper›PMID 42718779›Full record

ArticleFrontiers in behavioral neuroscience2026

Impaired behavioral flexibility and coping strategy shifts in 5xFAD mice in the novel Destruction-Building Test.

Eugenia Ahremenko, Alexander Andreev, Kirill Chaprov, Eduard Korkotian

Abstract read
In one paragraph

Article in Frontiers in behavioral neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eugenia AhremenkoFaculty of Chemistry, Perm State University, Perm, Russia.
Alexander AndreevFaculty of Chemistry, Perm State University, Perm, Russia.
Kirill ChaprovInstitute of Physiologically Active Compounds, Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Russia.
Eduard KorkotianFaculty of Chemistry, Perm State University, Perm, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The assessment of early ethological markers of neurodegeneration in Alzheimer's disease (AD) remains a pivotal task in preclinical research. This study evaluates the diagnostic potential of the "Destruction-Building Test" (DBT), a novel assay based on the innate manipulative behaviors of rodents-specifically material shredding and complex nest-building-as an early indicator of neurodegenerative changes. Methods: Investigations were conducted on hemizygous 5xFAD transgenic mice and wild-type (WT) controls of both sexes at 15, 28, and 42 weeks of age. The protocol included a 24-h habituation phase with continuous actigraphy to assess spontaneous locomotor activity (SLA), followed by a 72-h phase of manipulative activity. Generalized Estimating Equations (GEE) were employed for statistical modeling. Results: We observed a systemic reduction in manipulative activity in 5xFAD mice, which was most pronounced in females starting from 15 weeks of age. GEE modeling confirmed that genotype and sex were the primary determinants of shredding deficits ( Discussion: These findings suggest that the DBT is highly sensitive to early neurodegenerative manifestations before the onset of gross motor deficits.Its methodological simplicity and robust diagnostic value position the DBT as an effective tool for the longitudinal screening of cognitive status in AD mouse models.

Indexed as

5XFAD miceActivities of Daily Living (ADLs)behavioral assaysDestruction-Building Test (DBT)manipulative performancesex differencesspontaneous locomotor activity (SLA)

Identifiers

PMID42718779
PMCPMC13553921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.